EGFR mutations were identified in nearly 52% of TP53/RB1 co‐altered LUAD (Figure 3C), suggesting that EGFR/TP53/RB1 triple‐mutant tumors may define a highly plastic subset with potential for SCLC transdifferentiate [20]. This evidence concerns the gene TP53 and small cell lung carcinoma.